These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

280 related items for PubMed ID: 9309756

  • 1. Amiodarone induced torsades de pointes with excessive QT dispersion following quinidine induced polymorphic ventricular tachycardia.
    Tran HT, Chow MS, Kluger J.
    Pacing Clin Electrophysiol; 1997 Sep; 20(9 Pt 1):2275-8. PubMed ID: 9309756
    [Abstract] [Full Text] [Related]

  • 2. Precordial QT interval dispersion as a marker of torsade de pointes. Disparate effects of class Ia antiarrhythmic drugs and amiodarone.
    Hii JT, Wyse DG, Gillis AM, Duff HJ, Solylo MA, Mitchell LB.
    Circulation; 1992 Nov; 86(5):1376-82. PubMed ID: 1423949
    [Abstract] [Full Text] [Related]

  • 3. Torsade de pointes induced by intravenous amiodarone therapy accompanied by marked augmentation of the transmural dispersion of repolarization in a patient with tachycardia-induced-cardiomyopathy.
    Yonai R, Kawabata M, Maeda S, Kawashima T, Tsuda Y, Nakasone T, Nakane H, Hirao K.
    Ann Noninvasive Electrocardiol; 2021 May; 26(3):e12810. PubMed ID: 33070441
    [Abstract] [Full Text] [Related]

  • 4. Proarrhythmic effects of intravenous quinidine, amiodarone, D-sotalol, and almokalant in the anesthetized rabbit model of torsade de pointes.
    Farkas A, Leprán I, Papp JG.
    J Cardiovasc Pharmacol; 2002 Feb; 39(2):287-97. PubMed ID: 11791015
    [Abstract] [Full Text] [Related]

  • 5. Torsades de pointes and QT prolongation due to a combination of loratadine and amiodarone.
    Atar S, Freedberg NA, Antonelli D, Rosenfeld T.
    Pacing Clin Electrophysiol; 2003 Mar; 26(3):785-6. PubMed ID: 12698686
    [Abstract] [Full Text] [Related]

  • 6. QT prolongation and development of torsades de pointes with the concomitant administration of oral erythromycin base and quinidine.
    Lin JC, Quasny HA.
    Pharmacotherapy; 1997 Mar; 17(3):626-30. PubMed ID: 9165570
    [Abstract] [Full Text] [Related]

  • 7. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs.
    Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH.
    JAMA; 1993 Dec 01; 270(21):2590-7. PubMed ID: 8230644
    [Abstract] [Full Text] [Related]

  • 8. Torsade de pointes induced by citalopram and amiodarone.
    Fayssoil A, Issi J, Guerbaa M, Raynaud JC, Heroguelle V.
    Ann Cardiol Angeiol (Paris); 2011 Jun 01; 60(3):165-8. PubMed ID: 21295285
    [Abstract] [Full Text] [Related]

  • 9. Torsade de pointes with amiodarone in a patient with previous torsade during beta-receptor blockade.
    Skanes AC, Morton BC, Green MS, Tang AS.
    Can J Cardiol; 1997 Apr 01; 13(4):383-6. PubMed ID: 9141970
    [Abstract] [Full Text] [Related]

  • 10. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
    Lu HR, Yan GX, Gallacher DJ.
    J Pharmacol Toxicol Methods; 2013 Apr 01; 68(2):250-259. PubMed ID: 23337247
    [Abstract] [Full Text] [Related]

  • 11. [Torsades de pointes ventricular tachycardia induced by intravenous amiodarone].
    Makai A, Rudas L, Liszkai G, Fazekas T.
    Orv Hetil; 2003 Feb 02; 144(5):241-7. PubMed ID: 12647553
    [Abstract] [Full Text] [Related]

  • 12. Role of transmural dispersion of repolarization in the genesis of drug-induced torsades de pointes.
    Antzelevitch C.
    Heart Rhythm; 2005 Nov 02; 2(2 Suppl):S9-15. PubMed ID: 16253930
    [Abstract] [Full Text] [Related]

  • 13. [Long QT syndrome induced by cordaron and quinidine].
    Mironchik EV, Dolgosheĭ TS, Liskovich TG, Madeshkina GA, Kokhkovski AB, Tyshchenko AD.
    Klin Med (Mosk); 2007 Nov 02; 85(3):69-71. PubMed ID: 17523411
    [Abstract] [Full Text] [Related]

  • 14. [Amiodarone therapy after sotalol-induced torsade de pointes: prolonged QT interval and QT dispersion in differentiation of pro-arrhythmic effects].
    van de Loo A, Klingenheben T, Hohnloser SH.
    Z Kardiol; 1994 Dec 02; 83(12):887-90. PubMed ID: 7846927
    [Abstract] [Full Text] [Related]

  • 15. A case series of drug-induced long QT syndrome and Torsade de Pointes.
    Tong KL, Lau YS, Teo WS.
    Singapore Med J; 2001 Dec 02; 42(12):566-70. PubMed ID: 11989578
    [Abstract] [Full Text] [Related]

  • 16. QTc prolongation and torsades de pointes due to a coadministration of fluoxetine and amiodarone in a patient with implantable cardioverter-defibrillator: Case report and review of the literature.
    Wei A, Peng J, Gu Z, Li J.
    Medicine (Baltimore); 2017 Dec 02; 96(49):e9071. PubMed ID: 29245320
    [Abstract] [Full Text] [Related]

  • 17. Torsade de pointes induced by intravenous and long-term oral amiodarone therapy in a patient with dilated cardiomyopathy.
    Yamada S, Kuga K, Yamaguchi I.
    Jpn Circ J; 2001 Mar 02; 65(3):236-8. PubMed ID: 11266201
    [Abstract] [Full Text] [Related]

  • 18. Early proarrhythmia during intravenous amiodarone treatment.
    Tomcsányi J, Merkely B, Tenczer J, Papp L, Karlócai K.
    Pacing Clin Electrophysiol; 1999 Jun 02; 22(6 Pt 1):968-70. PubMed ID: 10392400
    [Abstract] [Full Text] [Related]

  • 19. Propafenone-induced torsade de pointes: cross-reactivity with quinidine.
    Hii JT, Wyse DG, Gillis AM, Cohen JM, Mitchell LB.
    Pacing Clin Electrophysiol; 1991 Nov 02; 14(11 Pt 1):1568-70. PubMed ID: 1721143
    [Abstract] [Full Text] [Related]

  • 20. Amiodarone-associated macroscopic T-wave alternans and torsade de pointes unmasking the inherited long QT syndrome.
    Wegener FT, Ehrlich JR, Hohnloser SH.
    Europace; 2008 Jan 02; 10(1):112-3. PubMed ID: 18006559
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.